Status:
COMPLETED
Management of Health-Related QoL Impairment, Including Pain, Depression and Anxiety, in People With Haemophilia A and B
Lead Sponsor:
Swedish Orphan Biovitrum
Conditions:
Haemophilia A
Haemophilia B
Eligibility:
All Genders
5+ years
Brief Summary
The puropse of this non-interventional register and survey study is to identify the patterns of prescribed pain, anti-depressive and anti-anxiety medication and management of pain, depression and anxi...
Eligibility Criteria
Inclusion
- Part A population will be defined by having:
- at least one health care contact with main diagnosis haemophilia A or haemophilia B, and/or;
- at least one prescription of factor VIII or factor IX concentrates, or;
- bypassing agents used in the treatment of PwH during the inclusion period.
- Part B1 population: Relevant physician at each HTC with direct and frequent patient contact.
- Part B2 population: PwH 5 years or older listed at participating HTCs
Exclusion
- NA
Key Trial Info
Start Date :
October 30 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 30 2020
Estimated Enrollment :
2300 Patients enrolled
Trial Details
Trial ID
NCT03276130
Start Date
October 30 2018
End Date
January 30 2020
Last Update
March 6 2024
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Swedish Orphan Biovitrum Research Site
Copenhagen, Denmark
2
Swedish Orphan Biovitrum Research Site
Helsinki, Finland
3
Swedish Orphan Biovitrum Research Site
Gothenburg, Sweden
4
Swedish Orphan Biovitrum Research Site
Malmo, Sweden